Search
R112
go.drugbank.com/drugs/DB06252ExperimentalR112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
X-376
go.drugbank.com/drugs/DB13104InvestigationalX-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]
Povetacicept
go.drugbank.com/drugs/DB18996InvestigationalPovetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).
Duvoglustat
go.drugbank.com/drugs/DB03206InvestigationalAn alpha-glucosidase inhibitor with antiviral action. Derivatives of deoxynojirimycin may have anti-HIV activity.
Synonyms: D-1-deoxynojirimycin, 1,5-deoxy-1,5-imino-D-mannitolPhorbol 12-myristate 13-acetate diester
go.drugbank.com/drugs/DB17045InvestigationalPhorbol 12-myristate 13-acetate diester is an inducer of neutrophil extracellular traps (NETs).[A253087]
Synonyms: 12-o-tetradecanoylphorbol-13-acetateTipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
TC-5231
go.drugbank.com/drugs/DB05333ExperimentalTC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder). … TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.
Wortmannin
go.drugbank.com/drugs/DB08059ExperimentalWortmannin is a steroid metabolite of _Penicillium funiculosum_ and _Talaromyces wortmannii_ fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).
Dubermatinib
go.drugbank.com/drugs/DB15187InvestigationalDubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).
Imdusiran
go.drugbank.com/drugs/DB19014InvestigationalImdusiran is under investigation in clinical trial NCT06245291 (Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection).
Synonyms: AB-729